{
    "clinical_study": {
        "@rank": "82295", 
        "arm_group": {
            "arm_group_label": "Type 2 diabetic women"
        }, 
        "biospec_descr": {
            "textblock": "The following parameters will be assessed:\n\n      Blood: ematology, glycated hemoglobin, fasting plasma glucose, fasting plasma insulin, total\n      cholesterol, HDL cholesterol, triglycerides, LDL cholesterol, creatinine, urea,\n      transaminases, electrolytes, homocysteine, high sensitivity C-reactive protein (hs-CRP),\n      metalloproteinase-2 (MMP-2), metalloproteinase-9 (MMP-9), soluble adhesion molecules\n      (sICAM-1, sVCAM-1), sE-selectin, lipoprotein (a) [Lp (a)], Plasminogen Activator Inhibitor-1\n      (PAI-1).\n\n      Urine: complete urinalysis, 24-hour microalbuminuria"
        }, 
        "biospec_retention": "Samples Without DNA", 
        "brief_summary": {
            "textblock": "Type 2 diabetes mellitus is becoming an increasingly problem for public health and it is\n      related with various complications such as sexual problems. The prevalence of erectile\n      dysfunction has been widely studied in men as a complication of diabetes; the prevalence of\n      sexual dysfunction in women, instead, has not been well investigated. The aim of this study\n      is to evaluate the prevalence of sexual dysfunction in type 2 diabetic women using\n      international validated questionnaires."
        }, 
        "brief_title": "Sexual Dysfunction in Type 2 Diabetic Women", 
        "completion_date": {
            "#text": "June 2016", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Sexual Dysfunction", 
            "Neuropathy"
        ], 
        "condition_browse": {
            "mesh_term": "Sexual Dysfunctions, Psychological"
        }, 
        "detailed_description": {
            "textblock": "In an estimated temporal space of about 3 years, 306 women will be recruited consecutively.\n\n      After collection of written informed consent, the following data will be collected:\n\n        -  History: type of diabetes, comorbidities, current medication, duration of diabetes and\n           complications, voluptuary habits such as tobacco smoke (both number of packets/year and\n           n\u00b0 packets/day), alcohol consumption, coffee consumption, physical activity.\n\n        -  Physical exam, general anthropometric parameters such as weight, height, circumference,\n           body mass index, waist-hip ratio, and blood pressure.\n\n        -  Assessment of glycemic variability (fasting plasma glucose and post-prandial glucose)\n\n        -  Each patient will be self-administered Female Sexual Function Index (FSFI) and Female\n           Sexual Distress Scale (FSDS) questionnaires to assess the prevalence of sexual\n           dysfunction and Self-Rating Anxiety Scale (SAS) and Self-Rating Depression Scale (SDS)\n           of Zung for an accurate assessment of the state of anxiety and depression.\n\n        -  We will collect blood and urine samples to assess: ematology, glycated hemoglobin,\n           fasting plasma glucose, fasting plasma insulin, total cholesterol, HDL cholesterol,\n           triglycerides, LDL cholesterol, creatinine, urea, transaminases, electrolytes, complete\n           urinalysis, 24-hour microalbuminuria, homocysteine, high sensitivity C-reactive protein\n           (hs-CRP), metalloproteinase-2 (MMP-2), metalloproteinase-9 (MMP-9), soluble adhesion\n           molecules (sICAM-1, sVCAM-1), sE-selectin, lipoprotein (a) [Lp (a)], Plasminogen\n           Activator Inhibitor-1 (PAI-1).\n\n        -  We will also conduct a clinical and instrumental exam of the foot using Neuropad,\n           recently validated as a screening tool for diabetic neuropathy. Patients will also\n           undergo autonomic tests (deep breathing, lying to standing, Valsalva maneuver, and\n           orthostatic hypotension).\n\n      We will also evaluate the presence of neuropathy through the administration of the Michigan\n      Neuropathy Screening Instrument (MNSI) and the Neuropathy Disability Score (NDS)."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  type 2 diabetes mellitus\n\n        Exclusion Criteria:\n\n          -  previous surgery for hysterectomy or ovariectomy\n\n          -  hormone replacement"
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years", 
            "sampling_method": "Probability Sample", 
            "study_pop": {
                "textblock": "Type 2 diabetic women"
            }
        }, 
        "enrollment": {
            "#text": "306", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "June 25, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01896648", 
            "org_study_id": "20120021266"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "July 6, 2013", 
        "location": {
            "contact": {
                "email": "giuseppe.derosa@unipv.it", 
                "last_name": "Giuseppe Derosa, MD, PhD"
            }, 
            "contact_backup": {
                "email": "pamelamaffioli@hotmail.it", 
                "last_name": "Pamela Maffioli, MD"
            }, 
            "facility": {
                "address": {
                    "city": "Pavia", 
                    "country": "Italy", 
                    "zip": "27100"
                }, 
                "name": "IRCCS Policlinico S. Matteo Foundation"
            }, 
            "investigator": [
                {
                    "last_name": "Giuseppe Derosa, MD, PhD", 
                    "role": "Principal Investigator"
                }, 
                {
                    "last_name": "Pamela Maffioli, MD", 
                    "role": "Sub-Investigator"
                }
            ], 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Italy"
        }, 
        "number_of_groups": "1", 
        "official_title": "Sexual Dysfunction in Type 2 Diabetic Women: Study on Prevalence and on Risk", 
        "other_outcome": {
            "description": "The presence of diabetic neuropathy will be assessed using dysautonomic tests (deep breathing, lying to standing, Valsalva maneuver  e orthostatic hypotension).\nThe prevalence of symmetric distal neuropathy will be assessed using:\nthe Neuropad test, developed as a simple visual indicator test to evaluate diabetic neuropathy\nthe Michigan Neuropathy Screening Instrument  (MNSI)\nthe Neuropathy Disability Score (NDS) The correlation will be analyzed using the Pearson correlation coefficient r", 
            "measure": "Correlation between sexual dysfunction and diabetic neuropathy", 
            "safety_issue": "No", 
            "time_frame": "36 months"
        }, 
        "overall_contact": {
            "email": "giuseppe.derosa@unipv.it", 
            "last_name": "Giuseppe Derosa, MD, PhD"
        }, 
        "overall_contact_backup": {
            "email": "pamelamaffioli@hotmail.it", 
            "last_name": "Pamela Maffioli, MD"
        }, 
        "overall_official": {
            "affiliation": "IRCCS Policlinico S. Matteo Foundation", 
            "last_name": "Giuseppe Derosa, MD, PhD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Italy: Ethics Committee", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Female Sexual Function Index (FSFI) is a 19-item questionnaire, developed as a brief, multidimensional self-report instrument for assessing the key dimensions of sexual function in women.", 
            "measure": "Female Sexual Function Index (FSFI)", 
            "safety_issue": "No", 
            "time_frame": "12 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01896648"
        }, 
        "responsible_party": {
            "investigator_affiliation": "University of Pavia", 
            "investigator_full_name": "Giuseppe Derosa", 
            "investigator_title": "Professor", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "description": "We will consider the following risk factors:\nSmoking status; Consume of alcohol; Obesity; Hepatic steatosis; Hypertension; Dyslipidemia; Chronic ischemic disease; Hyperuricemia; Chronic kidney disease; Retinopathy; Neuropathy; Vasculopathy.\nCorrelations between sexual dysfunction and single risk factors will be analyzed using the Pearson correlation coefficient r.", 
            "measure": "Prevalence of sexual dysfunction risk factors", 
            "safety_issue": "No", 
            "time_frame": "36 months"
        }, 
        "source": "University of Pavia", 
        "sponsors": {
            "collaborator": {
                "agency": "IRCCS Policlinico S. Matteo", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "University of Pavia", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "June 2013", 
        "study_design": "Observational Model: Cohort", 
        "study_type": "Observational", 
        "verification_date": "July 2013"
    }
}